Nephros Launches New HydraGuard 20” UltraFilter
Nephros (Nasdaq: NEPH) has launched the HydraGuard 20" UltraFilter, expanding its filtration technology portfolio. The new filter offers higher-volume capacity and flow rate while removing bacteria, viruses, and endotoxins. This product enables Nephros to enter new markets, particularly medical device manufacturing and pharmaceutical production, supporting compliance with water quality standards like ANSI/AAMI ST108.
The filter builds upon existing HydraGuard technology, previously to dialysis water purification, and provides exceptional retention of microbiological contaminants through size exclusion, offering more reliable performance compared to charged membranes.
Nephros (Nasdaq: NEPH) ha lanciato il HydraGuard 20" UltraFilter, ampliando il suo portafoglio di tecnologie di filtrazione. Il nuovo filtro offre una maggiore capacità di volume e portata, rimuovendo batteri, virus e endotossine. Questo prodotto consente a Nephros di entrare in nuovi mercati, in particolare nella produzione di dispositivi medici e farmaceutici, supportando la conformità agli standard di qualità dell'acqua come ANSI/AAMI ST108.
Il filtro si basa sulla tecnologia HydraGuard esistente, precedentemente utilizzata per la purificazione dell'acqua per la dialisi, e fornisce un'eccezionale ritenzione dei contaminanti microbiologici attraverso l'esclusione per dimensioni, offrendo prestazioni più affidabili rispetto alle membrane cariche.
Nephros (Nasdaq: NEPH) ha lanzado el HydraGuard 20" UltraFilter, expandiendo su cartera de tecnologías de filtración. El nuevo filtro ofrece una mayor capacidad de volumen y tasa de flujo mientras elimina bacterias, virus y endotoxinas. Este producto permite a Nephros ingresar a nuevos mercados, particularmente en la fabricación de dispositivos médicos y en la producción farmacéutica, apoyando el cumplimiento de los estándares de calidad del agua como ANSI/AAMI ST108.
El filtro se basa en la tecnología HydraGuard existente, utilizada anteriormente para la purificación de agua de diálisis, y proporciona una retención excepcional de contaminantes microbiológicos a través de la exclusión por tamaño, ofreciendo un rendimiento más confiable en comparación con las membranas cargadas.
Nephros (Nasdaq: NEPH)는 HydraGuard 20" UltraFilter를 출시하여 필터링 기술 포트폴리오를 확장했습니다. 새로운 필터는 더 높은 용적 용량과 유량을 제공하며 박테리아, 바이러스 및 내독소를 제거합니다. 이 제품은 Nephros가 의료 기기 제조 및 제약 생산과 같은 새로운 시장에 진입할 수 있게 하며, ANSI/AAMI ST108과 같은 수질 기준 준수를 지원합니다.
이 필터는 기존의 HydraGuard 기술을 기반으로 하며, 이전에는 투석 수질 정화에 사용되었으며, 크기 배제를 통해 미생물 오염 물질의 뛰어난 유지 성능을 제공하여 하전막보다 더 신뢰할 수 있는 성능을 제공합니다.
Nephros (Nasdaq: NEPH) a lancé le HydraGuard 20" UltraFilter, élargissant ainsi son portefeuille de technologies de filtration. Le nouveau filtre offre une capacité de volume et un débit supérieurs tout en éliminant les bactéries, les virus et les endotoxines. Ce produit permet à Nephros de pénétrer de nouveaux marchés, notamment la fabrication de dispositifs médicaux et la production pharmaceutique, en soutenant la conformité aux normes de qualité de l'eau telles que l'ANSI/AAMI ST108.
Le filtre repose sur la technologie HydraGuard existante, utilisée auparavant pour la purification de l'eau de dialyse, et offre une rétention exceptionnelle des contaminants microbiologiques grâce à l'exclusion par taille, offrant des performances plus fiables par rapport aux membranes chargées.
Nephros (Nasdaq: NEPH) hat den HydraGuard 20" UltraFilter auf den Markt gebracht und damit sein Portfolio an Filtrationstechnologien erweitert. Der neue Filter bietet eine höhere Volumenkapazität und Durchflussrate und entfernt Bakterien, Viren und Endotoxine. Dieses Produkt ermöglicht es Nephros, in neue Märkte einzutreten, insbesondere in die Herstellung von Medizinprodukten und pharmazeutischen Produktionen, und unterstützt die Einhaltung von Wasserqualitätsstandards wie ANSI/AAMI ST108.
Der Filter baut auf der bestehenden HydraGuard-Technologie auf, die zuvor zur Reinigung von Dialysewasser verwendet wurde, und bietet eine außergewöhnliche Retention von mikrobiologischen Kontaminanten durch Größeausschluss, wodurch eine zuverlässigere Leistung im Vergleich zu geladenen Membranen gewährleistet wird.
- Expansion into new markets (medical device manufacturing and pharmaceutical production)
- Enhanced product capabilities with higher-volume capacity and flow rate
- Potential for increased revenue through market expansion
- Addresses compliance requirements for ANSI/AAMI ST108 standards
- None.
Insights
The launch of the HydraGuard 20" UltraFilter represents a significant market expansion opportunity for Nephros. The product strategically targets high-value sectors like medical device manufacturing and pharmaceutical production, where water purity requirements are stringent and regulatory compliance is mandatory. The timing aligns well with the recent ANSI/AAMI ST108 standards, creating a compelling market entry point.
For a micro-cap company with a market cap of just
The HydraGuard 20" model's technical specifications mark a notable advancement in filtration technology. The filter's ability to handle higher volumes while maintaining effectiveness against bacteria, viruses and endotoxins through size exclusion is particularly impressive. This method offers more reliable contamination control compared to charged membrane alternatives, which can be inconsistent over time.
The product's compliance with ANSI/AAMI ST108 standards positions it as a turnkey solution for sterile processing departments facing new regulatory requirements. The expanded capacity and flow rate capabilities make it suitable for industrial-scale applications, addressing a key limitation of previous models.
New Filter Targets Additional Industries and Water Quality Compliance
SOUTH ORANGE, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Nephros, Inc. (Nasdaq: NEPH) Nephros, Inc., a leader in advanced filtration technology, is excited to announce the release of the HydraGuard 20” UltraFilter. This latest innovation enables the company to break into new markets and aid in compliance with water quality standards such as ANSI/AAMI ST108.
The HydraGuard 20” model is an extension of the existing HydraGuard and designed to provide a higher-volume capacity and flow rate, while removing harmful contaminants like bacteria, viruses, and endotoxins. With this product, Nephros is poised to serve a broader range of customers, including companies within medical device manufacturing and pharmaceutical production, to ensure the highest level of water purity for industries that require strict quality standards.
“We are thrilled to introduce this new product to the market,” said Robert Banks, President & CEO of Nephros. “Previously, a 20” model of our 222 O-ring cartridges was only available for use in dialysis water purification. Now, we can expand the application of our infection control technology into industries and settings which require the highest levels of water purity to prevent contamination and ensure product safety.”
Robert Banks continued, “By targeting new industries like sterile processing and pharmaceuticals, where water safety is mission-critical, Nephros is positioning itself for sales growth. We will continue to pursue innovation with the goals of increased market share and further strengthening of our position as a leader in filtration technology.”
The HydraGuard 20” filter opens the door to expanded revenue opportunities and greater support for businesses and facilities struggling to establish or maintain compliance with strict regulatory standards. Most notably, the issuance of ANSI/AAMI ST108 in late 2023 introduced new metrics for sterile processing, such as water testing schedules and parameters for bacteria and endotoxin presence. Solutions like the HydraGuard, along with other Nephros infection control products, provide exceptional retention of microbiological contaminants and support purification of water beyond the new standards. Regarding endotoxins specifically, Nephros in-line filters have the additional benefit of performance based on size exclusion, which achieves reliable and consistent retention compared to the more typical charged membranes.
About Nephros
Nephros is a leading provider of filtration products to the medical, commercial, and industrial markets, offering a wide range of solutions that deliver superior filtration performance. With its advanced hollow-fiber technology and effective commercial filter media, Nephros products help protect against waterborne contaminants, ensuring the highest level of water quality.
For more information about Nephros and its support for water safety, visit nephros.com
Forward-Looking Statements
This release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding Nephros’ expected future business and revenue from the marketing and sale of the HydraGuard 20” UltraFilter, its goals to increase market share, and other statements that are not historical facts, including statements that may be accompanied by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including inflationary factors and general economic conditions, changes in business and competitive conditions, the availability of capital when needed, dependence on third-party manufacturers, distributors and researchers, and regulatory reforms. These and other risks and uncertainties are detailed in Nephros’ reports filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2022, which it may update in Part II, Item 1A – Risk Factors in its Quarterly Reports on Form 10-Q that it has filed or will file hereafter. Nephros does not undertake any responsibility to update the forward-looking statements in this release.
Investor Relations Contacts:
Kirin Smith, President
PCG Advisory, Inc.
(646) 823-8656
ksmith@pcgadvisory.com
Robert Banks, CEO
Nephros, Inc.
(201) 343-5202
robert.banks@nephros.com
Judy Krandel, CFO
Nephros, Inc.
(201) 343-5202
judy.krandel@nephros.com
FAQ
What is the new product launched by Nephros (NEPH) in October 2024?
What markets does the new HydraGuard 20" UltraFilter target?
What contaminants does Nephros's new HydraGuard 20" filter remove?
How does Nephros's HydraGuard filter differ from typical membrane filters?
